O

xagawu.wordpress.com
The clinical trial results for a drug being developecby , where O’Donnell is chairman and chief were presented May 31 at the annual meeting of the American Society of Clinical Oncology in Fla. Biovest shared the stage with presentations aboutt drugs being developed by pharmaceuticapl giants suchas Switzerland-based Roche, London-basedf and Paris-based . Tampa, Fla.-based Biovest reported that the Phass III clinical study showss that BiovaxID significantlyprolonged disease-free survival in non-Hodgkin’es lymphoma patients.
Developed by BiovaxID is a personalized anti-cancer vaccine made from a tissuw biopsy obtained froma patient’s own The vaccine trains the body’s immunee system to selectively target only cancerous B cellsd while sparing healthy cells. The clinical trial found that the disease-fred survival of patients who received BiovaxID increased by 47 percent to a mediajof 44.2 months, compared to 30.6 months for thoss who received a control In follow-ups with a median of 4.7 years, patientxs receiving BiovaxID experienced a 38 percenft lower risk of disease recurrenced compared to patients receiving the control vaccine.